Evidence map›Paper›PMID 34873656›Full record

ReviewArchives of microbiology2021

COVID-19: comprehensive review on mutations and current vaccines.

Ananda Vardhan Hebbani, Swetha Pulakuntla, Padmavathi Pannuru, Sreelatha Aramgam, Kameswara Rao Badri, Vaddi Damodara Reddy

Open access · bronzeAbstract readReview
In one paragraph

Review in Archives of microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Article
  10. SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  11. Aptamer-Based Strategies to Address Challenges in COVID-19 Diagnosis and Treatments.Interdisciplinary perspectives on infectious diseases · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. SARS-CoV-2 in brief: from virus to prevention.Osong public health and research perspectives · 2022
    Article
  16. Iranian journal of basic medical sciences · 2022
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Ananda Vardhan Hebbani *Department of Biochemistry, Indian Academy Degree College, Bengaluru, 560 043, India.
Swetha Pulakuntla *Department of Biochemistry, REVA University, Bengaluru, 560064, India.
Padmavathi PannuruDR Biosciences, Research and Development Institute, Bettahalasur, Bengaluru, 562157, India.
Sreelatha AramgamDepartment of Biochemistry, REVA University, Bengaluru, 560064, India.
Kameswara Rao BadriDepartment of Pharmacology and Toxicology, Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta, GA, 30310, USA. kbadri@msm.edu.
Vaddi Damodara ReddyDepartment of Biochemistry, REVA University, Bengaluru, 560064, India. damodara.reddyv@reva.edu.in.ORCID http://orcid.org/0000-0002-4441-0859
REVA University · INEmory University · USInstitute of Bioinformatics and Applied Biotechnology · INMorehouse School of Medicine · US

Funding

Science and Engineering Research Board SB/S2/RJN-043/2014 dated 17.12.2015
6 · The paper itself

Abstract

Viral outbreaks had been a threat for the human race for a long time. Several epidemics and pandemics have been reported in the past with serious consequences on human health and subsequent social and economic aspects. According to WHO, viral infections continue to be a major health concern globally. Novel coronavirus, SARS-CoV-2 (Severe acute respiratory syndrome coronavirus-2) causes the most recent infectious pandemic disease, COVID-19 (Coronavirus disease-19). As of now, there were 249 million infections of COVID-19 worldwide with a high mortality of more than 5 million deaths reported; and the number of new additional cases is drastically increasing. Development of therapies to treat the infected cases and prophylactic agents including vaccines that are effective towards different variants are crucial to curtail the COVID-19 pandemic. Owing to the fact that there is a high mortality and morbidity rate along with the risk of virus causing further epidemic outbursts, development of additional effective therapeutic and preventive strategies are highly warranted. Prevention, early detection and treatment will reduce the spread of COVID-19 pandemic. The present review highlights the novel mutations and therapeutic updates associated with coronaviruses along with the clinical manifestations-diagnosis, clinical management and, prophylactic and therapeutic strategies of COVID-19 infection.

Indexed as

COVID-19VaccinesHumansMutationPandemicsSARS-CoV-2VaccinesClinical managementCOVID-19MutationsSARS-CoV-2Therapeutic strategies

Identifiers

PMID34873656
PMCPMC8647783
OpenAlexW4200492563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.